Stay updated on PAAP for Pralsetinib in NSCLC and MTC Clinical Trial
Sign up to get notified when there's something new on the PAAP for Pralsetinib in NSCLC and MTC Clinical Trial page.

Latest updates to the PAAP for Pralsetinib in NSCLC and MTC Clinical Trial page
- Check2 days agoChange DetectedNew Help/Information sections were added (How to Read a Study Record, Common Questions, How to Join a Study). The Intervention/Treatment label has been standardized, and the previous 'Intervention / Treatment' label and the 'Revision: v3.5.5' note were removed.SummaryDifference0.6%

- Check9 days agoChange DetectedThe page revision tag updated from v3.5.4 to v3.5.5. This appears to be a minor software update and does not change the study content.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe page now displays Revision: v3.5.4, replacing the previous v3.5.3. This indicates a small update to the page's revision tag.SummaryDifference0.1%

- Check51 days agoChange DetectedThe page revision label was updated from v3.5.2 to v3.5.3, indicating a minor version change to the site display rather than a change to the clinical trial content.SummaryDifference0.1%

- Check58 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check73 days agoChange DetectedMedullary thyroid carcinoma is now listed as a condition, and the Genetic and Rare Diseases Information Center has been added to the Resources section.SummaryDifference0.2%

Stay in the know with updates to PAAP for Pralsetinib in NSCLC and MTC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PAAP for Pralsetinib in NSCLC and MTC Clinical Trial page.